[No matter how many times this happens,  the FDA helps these manufacturers continue to distribute these drugs.  Children and the elderly became the target populations for psychotropic drugs several years ago. I urge everyone to share this with everyone you can.  Email, mail, or fax it to doctors and facilities for the elderly in your area. ;  Very few people will be removed from these drugs due to this. ; Those who are will suffer horrible withdrawal and may even die within a few months of discontinuing these drugs.  Of course, remaining on them also heightens the possibility of death from them. ;   I wish I could say something more positive, but I can't.  After spending almost three months in the care of conventional medicine practitioners, I am amazed that more people aren't killed by them.   ; --Catherine]




Information for Healthcare Professionals
Antipsychotics

---

FDA ALERT [6/16/2008]:  FDA is notifying healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. 

In April 2005, FDA notified healthcare professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death.  Since issuing that notification, FDA has reviewed additional information that indicates the risk is also associated with conventional antipsychotics.

Antipsychotics are not indicated for the treatment of dementia-related psychosis.  ;

This information reflects FDA's current analysis of data available to FDA concerning these drugs. FDA intends to update this sheet when additional information or analyses become available.

---

To report any unexpected adverse or serious events associated with the use of these drugs, please contact the FDA MedWatch program and complete a form on line at http://www.fda.gov/medwatch/report/hcp.htm or report by fax to 1-800-FDA-0178, by mail using the postage-paid address form provided on line, or by telephone to 1-800-FDA-1088.

FDA is requiring the manufacturers of conventional antipsychotic drugs to add a Boxed Warning and Warning to the drugs' prescribing information about the risk of mortality in elderly patients treated for dementia-related psychosis similar to the Boxed Warning and Warning added to the prescribing information of the atypical antipsychotic drugs in 2005.*  See the last page of this document for a list of conventional and atypical antipsychotic drugs.

Considerations for Healthcare Professionals

• Elderly patients with dementia-related psychosis treated with conventional or atypical antipsychotic drugs are at an increased risk of death.

• Antipsychotic drugs are not approved for the treatment of dementia-related psychosis.  Furthermore, there is no approved drug for the treatment of dementia-related psychosis.  Healthcare professionals should consider other management options.

• Physicians who prescribe antipsychotics to elderly patients with dementia-related psychosis should discuss this risk of increased mortality with their patients, patients' families, and caregivers.

Background Information and Data

Previously, in April 2005, FDA informed healthcare professionals and the public about the increased risk of mortality in elderly patients receiving atypical antipsychotic drugs to treat dementia-related psychosis (April 2005 Public Health Advisory and Information for Healthcare Professionals).  At that time, the analyses of 17 placebo-controlled trials that enrolled 5377 elderly patients with dementia-related behavioral disorders revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients.  Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g. pneumonia) in nature.  Based on this analysis, FDA requested that the manufacturers of atypical antipsychotic drugs include information about this risk in a Boxed Warning and the Warnings section of the drugs' prescribing information.

Recently, two observational epidemiological studies^1,2 were published that examined the  risk of death in patients who were treated with conventional antipsychotic drugs.

Gill et al.¹ performed a retrospective cohort study in Ontario, Canada of 27,259 adults, 66 years of age or older, with a diagnosis of dementia between April 1997 and March 2002.  The investigators compared the risk for death with use of an atypical antipsychotic versus no antipsychotic and the risk for death with use of a conventional antipsychotic versus an atypical antipsychotic. They found that  atypical antipsychotics were associated with increased mortality as compared to no antipsychotic use as early as 30 days and persisting until study end at 180 days. The investigators found that conventional antipsychotic use showed a marginally higher risk of death compared with atypical antipsychotic use. The causes of death were not reported in this study.  

Schneeweiss et al.² performed a retrospective cohort study in British Columbia, Canada of 37,241 adults, 65 years of age or older, who were prescribed conventional (12,882) or atypical (24,359) antipsychotic medications for any reason between January 1996 and December 2004. The investigators compared the 180-day all cause mortality with use of a conventional antipsychotic versus an atypical antipsychotic. They found that the risk of death in the group of patients treated with conventional antipsychotic medications was comparable to, or possibly greater than, the risk of death in the group of patients treated with atypical antipsychotic medications. The causes of death with the highest relative risk were cancer and cardiac disease. 

FDA considers that the methodological limitations in these two studies preclude any conclusion  that conventional antipsychotics have a greater risk of death with use than atypical antipsychotics. FDA has determined, however, that the overall weight of evidence, including these studies, indicates that the conventional antipsychotics share the increased risk of death in elderly patients with dementia-related psychosis that has been observed for the atypical antipsychotics.  The prescribing information for all antipsychotic drugs will now include the same information about this risk in a Boxed Warning and the Warnings section.

References

1.  Gill SS et al.  Antipsychotic drug use and mortality in older adults with dementia.  Ann Intern Med.  2007;146:775-786

2.  Schneeweiss S et al.  Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.  CMAJ. ; 2007;176:627-632.

Conventional Antipsychotic Drugs	Atypical Antipsychotic Drugs
Compazine (prochlorperazine)        ;           ;    	Abilify (aripiprazole)
Haldol (haloperidol)  	Clozaril (clozapine)
Loxitane (loxapine)  ;  	FazaClo (clozapine)
Mellaril (thioridazine)     ;      	Geodon (ziprasidone)
Moban (molindrone)	Invega (paliperidone)
Navane (thithixene)  	Risperdal (risperidone)
Orap (pimozide)         	Seroquel (quetiapine)
Prolixin (fluphenazine)     ;      	Zyprexa (olanzapine)
Stelazine (trifluoperazine)          ;        	Symbyax (olanzapine and fluoxetine)
Thorazine (chlorpromazine) ;  
Trilafon (perphenazine)

--
Regards,
Catherine

Messages in this topic (1) Reply (via web post) | Start a new topic

.